CAR T-cell therapy with Dr. Mazyar Shadman
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
CAR T-cell therapy with Dr. Mazyar Shadman
-
Narrated by:
-
By:
About this listen
Dr. Mazyar Shadman is a blood cancer specialist at Fred Hutch Cancer Center who focuses on lymphoid malignancies. In a conversation with Bonnie Rochman, they explore the advancements in CAR T-cell therapy, particularly for large B-cell lymphoma, highlighting its impact on patient outcomes and survival rates.
Takeaways
- CAR T therapy is a significant advancement in cancer treatment.
- The future of cancer treatment may heavily rely on CAR T advancements.
- CAR T therapy represents a shift in cancer care paradigms.
- It is particularly effective for large B-cell lymphoma.
- Patients with relapsed disease historically had limited survival chances.
- CAR T therapy has improved outcomes for high-risk patients.
- 30 to 40% of patients are now being cured with CAR T therapy.
- The treatment offers better quality of life compared to standard care.
- Ongoing research is crucial for further advancements in CAR T.
- Patient selection is key for the success of CAR T therapy.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.